Bronchodilator reversibility (BDR) - should we measure it in adults with symptoms but without obstructed spirometry?
M. Bennett (Manchester, United Kingdom), S. Drake (Manchester, United Kingdom), L. Healy (Manchester, United Kingdom), R. Tudge (Manchester, United Kingdom), L. Lowe (Manchester, United Kingdom), L. Willmore (Manchester, United Kingdom), L. Willmore (Manchester, United Kingdom), J. Mitchell (Manchester, United Kingdom), G. Kerry (Manchester, United Kingdom), C. Murray (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom), A. Simpson (Manchester, United Kingdom)
Source: Virtual Congress 2021 – Primary care diagnosis and multimorbidities
Session: Primary care diagnosis and multimorbidities
Session type: E-poster
Number: 3626
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Bennett (Manchester, United Kingdom), S. Drake (Manchester, United Kingdom), L. Healy (Manchester, United Kingdom), R. Tudge (Manchester, United Kingdom), L. Lowe (Manchester, United Kingdom), L. Willmore (Manchester, United Kingdom), L. Willmore (Manchester, United Kingdom), J. Mitchell (Manchester, United Kingdom), G. Kerry (Manchester, United Kingdom), C. Murray (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom), A. Simpson (Manchester, United Kingdom). Bronchodilator reversibility (BDR) - should we measure it in adults with symptoms but without obstructed spirometry?. 3626
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: